
Paradigm’s Kurt Mussina discusses why scale should drive operational efficiency, not consolidation into single-site studies.
As biopharmaceutical companies form partnerships with vendors for R&D, they can learn important lessons about outsourcing from the vastly different experiences of Toyota, Honda and their American counterparts.






